[As filed with the Securities and Exchange Commission on
September 8, 1997]
[Registration No. 333-25661]
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[AMENDMENT NO. 2 TO]
FORM S-3
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
CYPROS PHARMACEUTICAL CORPORATION
(Exact name of Registrant as specified in its charter)
California 2714 Loker Avenue West 33-0476164
(State or other Carlsbad, California (I.R.S. Employer
jurisdiction of 92008 Identification
incorporation (760) 929-9500 Number)
organization)
(Address, including zip code, and
telephone number, including area code,
of Registrant's principal executive offices)
David W. Nassif
Vice President and Chief Financial Officer
CYPROS PHARMACEUTICAL CORPORATION
2714 Loker Avenue West
Carlsbad, California 92008
(760) 929-9500
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copy to:
M. Wainwright Fishburn, Esq.
COOLEY GODWARD LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121
(619) 550-6000
__________________________
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this
Registration Statement.
If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans,
please check the following box. [ ]
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans,
check the following box. [ X ]
If this Form is filed to register additional securities for an
offering pursuant to Rule 462 (b) under the Securities Act,
please check the following box and list the Securities Act
registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule
462 (c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.
[ ]
If delivery of the prospectus is expected to be made pursuant to
Rule 434, please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
Title of Amount to Proposed Proposed Amount of
each class be maximum maximum registration
of registered offering price aggregate fee
securities (1) per share (1) offering
to be price (1)
registered
Common
Stock, no 1,378,037 $3.78-$4.625 $5,702,117 $1,727.91
par value shares
(1) Estimated in accordance with Rule 457(c) solely for the
purpose of computing the amount of the registration fee. The
price per share and the aggregate offering price are based upon
(a) 750,000 shares of Common Stock being carried forward from the
Registrant's Registration Statement on Form S-3 (No. 333-17501)
previously filed with the Commission on December 6, 1996 pursuant
to Rule 429 of the Securities Act, calculated on the basis of the
average of the high and low sales price of the Registrant's
Common Stock as reported on the Nasdaq National Market System
("Nasdaq") on December 3, 1996 and (b) 542,199 shares of Common
Stock being carried forward from the original filing of this
Registration Statement on Form S-3 filed with the Commission on
April 23, 1997 pursuant to Rule 429 of the Securities Act,
calculated on the basis of the average of the high and low sales
price of Registrant's Common Stock as reported on Nasdaq on April
21, 1997 and (c) 85,838 shares of Common Stock being registered
pursuant to this Amendment No. 1 to Registration Statement,
calculated on the basis of the average of the high and low sales
prices of Registrant's Common Stock as reported on Nasdaq on
August 25, 1997. The portion of the registration fee attributable
to the shares of Common Stock previously registered and the
shares of Common Stock covered by the original filing of this
Registration Statement were paid concurrently with the
Registrant's filing of such Registration Statements on Form S-3.
The following chart shows the calculation of the registration
fee:
Type of Number of Proposed Proposed Amount of
Shares Shares maximum maximum registration
offering aggregate fee
price offering
per price
share
Common Stock 750,000 $3.78 $2,835,000 $859.09
previously
registered
pursuant to
Registration
Statement
No. 333-
17501
Common Stock 542,199 $4.625 $2,507,670 $759.90
initially
registered
pursuant to
this
Registration
Statement
Common 85,838 $4.1875 $359,447 $108.92
Stock
initially
registered
pursuant to
Amendment
No. 1 to
Registration
Statement
The Registrant hereby amends this Registration Statement on such
date or dates as may be necessary to delay its effective date
until the Registrant shall file a further amendment that
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement
shall become effective on such date as the Commission, acting
pursuant to said Section 8(a), may determine.
This Registration Statement contains a combined prospectus
pursuant to Rule 429 under the Securities Act which relates to
the prospectus contained in the Registration Statement on Form S-
3 (No. 333-17501) previously filed by the Registrant on December
6, 1996.
[SUBJECT TO COMPLETION, DATED September 8, 1997]
P R O S P E C T U S
1,378,037 Shares
Cypros Pharmaceutical Corporation
Common Stock
______________________________
This Prospectus relates to 1,378,037 shares (the "Shares") of
Common Stock, no par value per share (the "Common Stock"), of
Cypros Pharmaceutical Corporation (the "Company"). The Shares may
be offered by shareholders of the Company (the "Selling
Shareholders") from time to time, as market conditions permit on
the Nasdaq National Market System, or otherwise, through ordinary
brokerage transactions, in negotiated transactions, at fixed
prices which may be changed, at market prices prevailing at the
time of sale, at prices related to such prevailing market prices
or at negotiated prices. The Selling Shareholders may effect
such transactions by selling the Shares to or through broker-
dealers, and all such broker-dealers may receive compensation in
the form of discounts, concessions or commissions from the
Selling Shareholders and/or the purchasers of the Shares for whom
such broker-dealers may act as agent or to whom they sell as
principal, or both (which compensation as to a particular broker-
dealer might be in excess of customary commissions). See
"Selling Shareholders" and "Plan of Distribution."
None of the proceeds from the sale of the Shares by the Selling
Shareholders will be received by the Company. The Company has
agreed to bear certain expenses (other than fees and expenses, if
any, of counsel or other advisors to the Selling Shareholders in
connection with the registration and sale of the Shares being
offered by the Selling Shareholders). The Company has agreed to
indemnify the Selling Shareholders against certain liabilities,
including certain liabilities under the Securities Act of 1933,
as amended.
[The Common Stock of the Company is traded on the NASDAQ National
Market System under the symbol "CYPR." On September 5, 1997, the
last sale price for the Common Stock as reported by NASDAQ was
$4.50 per share.]
______________________________
The Common Stock offered hereby involves a high degree of risk.
See "Risk Factors" beginning on page 3.
______________________________
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SE
CURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY
STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY
OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
[The date of this Prospectus is September , 1997]
The information contained herein is subject to completion or ame
ndment. A registration statement relating to these securities has
been filed with the Securities and Exchange Commission. These
securities may not be sold nor may offers to buy be accepted
prior to the time the registration statement becomes effective.
This prospectus shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any State in which such offer, solicitation
or sale would be unlawful prior to registration or
qualification under the securities laws of any such State.
THE COMPANY
Cypros Pharmaceutical Corporation (the "Company") was founded in
California in 1990 and is engaged in the development and
marketing of drug products for the hospital market. It is
currently marketing three injectable products and is developing
two small molecule therapeutic drugs, CPC-111 and CPC-211, for
the treatment of disorders, such as stroke, traumatic head
injury, congestive heart failure, cardiac surgery, and sickle
cell crisis, all of which are characterized by ischemia (impaired
blood flow), which interrupts the delivery of both glucose and
oxygen to tissue. The Company's executive offices are located at
2714 Loker Avenue West, Carlsbad, California 92008, and its
telephone number is (760) 929-9500.
RISK FACTORS
Except for the historical information contained herein, the
discussion in this Prospectus contains forward-looking statements
that involve risks and uncertainties. The Company's actual
results could differ materially from those discussed here.
Factors that could cause or contribute to such differences
include, but are not limited to, those discussed in the following
risk factors as well as those discussed elsewhere in this
Prospectus and any documents incorporated herein by reference.
The following factors, in addition to those discussed elsewhere
in this Prospectus, or incorporated herein by reference, should
be carefully considered in evaluating the Company and its
business.
Continuing Operating Losses
The Company reported a net loss of $1,471,014 or $0.12 per share
for the quarter ended April 30, 1997, compared to a loss of
$787,419 or $0.07 per share for the prior-year period and a net
loss of $5,247,711 or $0.44 per share for the nine months ended
April 30, 1997, compared to a loss of $2,168,359 or $0.19 per
share for the prior-year period. The Company expects that it will
continue to incur operating losses as it increases expenditures
for clinical testing, Investigational New Drug Application and
New Drug Application filings and other regulatory activities,
U.S. patent prosecution, and product acquisition and sales and
marketing activities. To achieve profitable operations, the
Company, alone or with others, must successfully develop, obtain
regulatory approval for, introduce, acquire, market and sell
additional products. There can be no assurance that the Company's
product acquisition and development efforts will result in
additional products, that required regulatory approvals will be
obtained with respect to all or any of its products now under
development or that any of these products will be commercially
successful.
Significant Capital Requirements; Need for Additional Financing
The development and commercialization of drugs requires the
commitment of significant capital expenditures. The Company
believes that existing capital resources and the cash flow from
its recently-acquired products will allow it to maintain its
current and planned operations for at least two years. In
addition to funds provided from exercises of its currently
outstanding Redeemable Class B Warrants (the "Warrants"), the
Company is seeking to obtain additional funds through public or
private equity financings, collaborative or other arrangements
with corporate partners or from other sources. There can be no
assurance that such additional financing can be obtained on
desirable terms or at all. If additional funds are not
available, the Company may be required to curtail significantly
or eliminate one or more of its research, discovery or
development programs or obtain funds through arrangements which
may require the Company to relinquish rights to certain of its
products.
Uncertainties Associated with Regulatory Approval
A marketed drug, its manufacturer and its manufacturing
facilities are subject to continual review and periodic
inspections, and later discovery of previously unknown problems
with a product, manufacturer or facility may result in
restrictions on such product or manufacturers, including a
withdrawal of the product from the market. Failure to comply with
the applicable regulatory requirements can, among other things,
result in fines, suspensions of regulatory approvals, product
recalls, operating restrictions and criminal prosecution.
Further, additional government regulation may be established
which could suspend or revoke regulatory approval of the
Company's products.
Unproven Products
In addition to its three approved drugs, the Company has other
products in various stages of development which are subject to
the risks inherent in drug development, including unforeseen
problems, delays, expenses and complications frequently
encountered with the early phases of research, development and
commercialization of products, the dependence on and attempts to
apply new and rapidly changing technology and the competitive
environment of the pharmaceutical industry. Many of these
factors may be beyond the Company's control, such as
unanticipated development requirements, testing, regulatory
compliance and manufacturing, production, and marketing problems
and expenses. The Company does not anticipate being able to
complete the development of its proposed products for a number of
years, if at all. All of the Company's drugs are subject to
extensive regulation and those in development will require
approval from the U.S. Food and Drug Administration (the "FDA")
and other regulatory agencies prior to commercial sales. The
Company may not complete the testing and regulatory approval
process for any of its products in development in the foreseeable
future and, accordingly, is unable to predict whether they will
be commercially successful. Further, there can be no assurance
that the Company's drugs under development will attain acceptance
by providers, payors or patients.
Patents, Proprietary Technology and Licenses
The Company's success is dependent in large measure upon its
ability to obtain patent protection for its drugs, maintain
confidentiality of its trade secrets and know-how and operate
without infringing upon the proprietary rights of third parties.
The Company has licensed rights to five U.S. patents from the
holders of the patents on CPC-111 and CPC-211, but each of these
licenses may be terminated in the event that the Company fails to
achieve certain milestones or accomplish certain other
contractual obligations. Upon any such termination, all of the
Company's rights would revert to the licensor. The termination of
the license covering CPC-111 or CPC-211 would have a material
adverse effect on the Company and would cause the Company to
focus its efforts on its remaining drug development programs
which are not as far advanced. There can be no assurance that the
Company will maintain the licenses in effect through the
successful development and commercialization of these drugs.
The U.S. patent position of pharmaceutical companies involves
many complex legal and technical issues and has recently been the
subject of much litigation. There is no clear policy
establishing the breadth of claims or the degree of protection
afforded under such patents. As a result, there can be no
assurance that any of the U.S. patent applications will be
approved, except where claims under an application have already
been examined and allowed, nor that the Company will develop
additional proprietary products that are patentable. There can
be no assurance that any U.S. patents issued to the Company or
its licensors will provide the Company with any competitive
advantages or will not be challenged by any third parties or that
patents issued to others will not have an adverse effect on the
ability of the Company to conduct its business.
Furthermore, because patent applications in the United States are
maintained in secrecy until issue, and because publication of
discoveries in the scientific and patent literature often lag
behind actual discoveries, the Company cannot be certain that it
was the first chronologically to make the inventions covered by
each of its pending patent applications or that it was the first
to file patent applications for such inventions. In the event
that a third party has also filed a patent application for any of
its inventions, the Company may have to participate in
interference proceedings declared by the United States Patent and
Trademark Office to determine priority of the invention, which
could result in substantial cost to the Company, even if the
eventual outcome is favorable to the Company. In addition, there
can be no assurance that the Company's patents, including those
of the licensors above, would be held valid by a court of law of
competent jurisdiction. If patents are issued to other companies
that contain competitive or conflicting claims which ultimately
may be determined to be valid, there can be no assurance that the
Company would be able to obtain a license to any of these U.S.
patents.
Under Title 35 of the United States Code, as amended by the
General Agreement on Tariffs and Trade implementing the Uruguay
Round Agreement Act of 1994 ("GATT"), patents that issue from
patent applications filed prior to June 8, 1995 will have a 17-
year period of enforceability as measured from the date of patent
issue, while those that issue from applications filed on or after
June 8, 1995 will have a 20-year period of enforceability as
measured from the date the patent application was filed or the
first claimed priority date, whichever is earlier. Patents that
issue from applications filed on or after June 8, 1995 may be
extended under the term extension provisions of GATT for a period
up to five years to compensate for any period of enforceability
lost due to interference proceedings, government secrecy orders
or appeals to the Board of Patent Appeals or the Federal Circuit.
Under the Drug Price Competition and Patent Term Restoration Act
of 1984, including amendments implemented under GATT (the "Patent
Term Restoration Act"), the period of enforceability of a first
or basic product patent or use patent covering a drug may be
extended for up to five years to compensate the patent holder for
the time required for FDA regulatory review of the product. This
law also establishes a period of time following FDA approval of
certain drug applications during which the FDA may not accept or
approve applications for similar or identical drugs from other
sponsors. Any extension under the Patent Term Restoration Act and
any extension under GATT are cumulative. There can be no
assurance that the Company will be able to take advantage of such
patent term extensions or marketing exclusivity provisions of
these laws. While the Company cannot predict the effect that such
changes will have on its business, the adoption of such changes
could have a material adverse effect on the Company's ability to
protect its proprietary information and sustain the commercial
viability of its products. Furthermore, the possibility of
shorter terms of patent protection, combined with the lengthy FDA
review process and possibility of extensive delays in such
process, could effectively further reduce the term during which a
marketed product could be protected by patents.
The Company also relies on trade secrets and proprietary know-
how. The Company has been and will continue to be required to
disclose its trade secrets and proprietary know-how not only to
employees and consultants, but also to potential corporate
partners, collaborators and contract manufacturers. Although the
Company seeks to protect its trade secrets and proprietary know-
how, in part by entering into confidentiality agreements with
such persons or organizations, there can be no assurance that
these agreements will not be breached, that the Company would
have adequate remedies for any breach or that the Company's trade
secrets will not otherwise become known or be independently
discovered by competitors.
Dependence on Others for Manufacture
The Company currently does not have any capability to manufacture
products under current good manufacturing practices ("cGMP") as
required by the FDA. It relies on third parties to manufacture
and formulate Ethamolinr, Glofil and Inulin and to manufacture
and formulate CPC-111 and CPC-211, its two drug candidates
currently in clinical trials. Although the Company believes that
it will be able to contract with alternative suppliers for its
products if its current suppliers are unable to supply the
Company with its needs for bulk and formulated drugs, there can
be no assurance that this will be the case or that the need to
contract with additional suppliers will not delay the Company's
ability to have its products manufactured. There can be no
assurance that these manufacturers will meet either the Company's
requirements for quality, quantity and timeliness or the FDA's
cGMP requirements or that the Company would be able to find a
substitute manufacturer for any of its products in the future.
In the event that the Company is unable to obtain or retain
contract manufacturers that can manufacture its products under
cGMP requirements, or to obtain manufacturing on commercially
acceptable terms, it may not be able to commercialize its
products as planned.
Potential Claims
Certain members of the Company's Scientific Advisory Board
("SAB") and certain Scientific Advisors who have developed
technology used for the Company's products are employees of
universities, research hospitals or other institutions. The
Company believes that such institutions have no claim to any of
the Company's inventions, technology or products. While no claim
has been asserted by any such institution, there can be no
assurance that such institutions will not assert claims to any or
all of such inventions, technology or products or that, if any
such institution does assert such rights, the Company, if it so
desires, will be able to acquire the rights thereto from such
institution at a commercially practical cost or at all.
Government Regulation
The Company's development, manufacture and sale of drug products
are subject to extensive and rigorous regulation by federal,
state, local and foreign governmental authorities. In particular,
products for human health are subject to substantial preclinical
and clinical testing and other approval requirements by the FDA
and comparable foreign regulatory authorities. The process for
obtaining the required regulatory approvals from the FDA and
other regulatory authorities takes many years and is very
expensive. There can be no assurance that any drug developed by
the Company will prove to meet all of the applicable standards to
receive marketing approval. There can be no assurance that any
such approvals will be granted on a timely basis, if at all.
Delays in and costs of obtaining these approvals could adversely
affect the Company's ability to commercialize its drugs and to
generate significant sales revenues. If regulatory approval of a
drug is obtained, such approval may involve restrictions and
limitations on the use of the drug.
Other conditions for an approval are based on the drug's
manufacture and the quality control procedures in place, such as
cGMP. Failure to insure compliance with cGMP requirements could
result in delay or termination of clinical trials or withdrawal
of an approval. Following market approval, the drug will continue
to be subject to compliance with applicable federal, state, local
and foreign laws and regulations. There can be no assurance that
the FDA will grant approval of any of the Company's drugs in a
timely manner or at all.
Governmental Reforms
Health care reform is an area of increasing national and
international attention and a priority of many elected officials
in the United States. Several proposals to modify the current
health care system in the United States to improve access and
control costs are currently being considered by federal and state
governments. It is uncertain what legislation, if any, will be
adopted or what actions governmental or private payors for health
care goods and services may take in response to proposed or
actual legislation in the United States. The Company cannot
predict the outcome of health care reform proposals or the effect
such reforms may have on its business.
Clinical Trial and Product Liability Claims and Uninsured Risks
The Company may be exposed to liability resulting from the
conduct of its clinical trials or the commercial use of its
drugs. Such liability might result from claims made directly by
patients, hospitals, clinics or other consumers or by
pharmaceutical companies or others manufacturing such drugs on
behalf of the Company. The Company currently has clinical trial
and product liability insurance, but there can be no assurance
that it will be adequate to protect the Company against
liability.
Competition and Technological Change
The products that the Company is marketing and the drugs that the
Company is developing may compete for market share with alternate
therapies. A number of companies are pursuing the development of
novel pharmaceuticals which target the same diseases as the
Company is targeting. Many of these competitors have
substantially greater capital resources, research and development
staffs and facilities than the Company. They may develop and
introduce products and processes competitive with those of the
Company. They represent significant long-term competition for
the Company. For certain of the Company's drugs, an important
factor in competition may be the timing of market introduction of
these competitive products. This timing will be based on the
effectiveness with which the Company or the competition can
complete clinical trials and approval processes and supply
quantities of these products to market. Competition among
products approved for sale will be based on, among other things,
efficacy, safety, reliability, price, marketing capability and
patent position.
The pharmaceutical industry has undergone rapid and significant
technological changes. The Company expects that the technologies
associated with its research and development will continue to
develop rapidly. There can be no assurance that the Company will
be able to establish itself in such fields or, if established,
that it will be able to maintain a competitive position.
Further, there can be no assurance that the development by others
of new or improved processes or products will not make the
Company's products and processes, if any, less competitive or
obsolete.
Dependence on Key Personnel
The Company's success also depends in large part on its ability
to attract and retain other qualified scientific and management
personnel. The Company faces competition for such persons from
other companies, academic institutions, government entities and
other organizations. There can be no assurance that the Company
will be successful in recruiting or retaining personnel of the
requisite caliber or in adequate numbers to enable it to conduct
its business as proposed. Furthermore, the Company's expected
expansion into activities requiring additional expertise in
manufacturing, sales and marketing will place increased demands
on the Company's resources and management skills.
Limited Sales and Marketing Capability
The commercialization of products such as the Company's drugs is
an expensive and time-consuming enterprise. The Company now has
sixhas no experience in sales, marketing or distributio sales
representatives for Ethamolinr, Glofil and Inulin and intends to
hire additional sales representatives as sales of those products
increase and/or other products are acquired by the Company. To
market any of its drugs directly, the Company expects to develop
a marketing and sales force with technical expertise and
supporting distribution capability. The Company believes that it
will be able to serve the hospital market in North America do so
with a 50 to 100 person sales and marketing staff. since its
drugs will be sold primarily to and administered in acute care
facilities rather than sold directly to physicians' offices or
retail drug stores. There can be no assurance that the Company
will be able to establish successfully sales and distribution
capabilities or be successful in gaining market acceptance for
its drugs or to obtain the assistance of any other pharmaceutical
company in these efforts if it should seek assistance.
Reimbursement
In both domestic and foreign markets, sales of the Company's
products will be dependent in part on the availability of
reimbursement from third party payors, such as government and
private insurance plans. Third party payors are increasingly
challenging the prices charged for medical products and services.
There can be no assurance that the Company's products will be
considered cost-effective, that reimbursement will be available
or, if available, that the payor's reimbursement policies will
not adversely affect the Company's ability to sell its products
profitably.
Outstanding Warrants and Options
There are currently outstanding 4,673,512 Class B Warrants.
Additional shares of Common Stock are issuable as follows: (i)
1,256,936 shares of Common Stock are reserved for issuance
pursuant to outstanding options under the Company's 1992 Stock
Option Plan and (ii) 181,500 shares are reserved for issuance
pursuant to outstanding options under the Company's 1993 Non-
Employee Directors' Stock Option Plan. Holders of warrants and
options are likely to exercise them when, in all likelihood, the
Company could obtain additional capital on terms more favorable
than those provided by the warrants and options. Further, while
the warrants and options are outstanding, they may adversely
affect the terms on which the Company could obtain additional
capital.
Potential Volatility of Stock Price
There has been significant volatility in the market price of
securities of biomedical companies in general. Announcements of
technological innovations or new commercial products by the
Company or its competitors, developments concerning proprietary
rights, clinical trial results, government policy or regulation,
relations with licensors or other corporate partners, general
market conditions or public concern as to the safety of
biomedical products and period to period fluctuations in revenues
and financial results may have a significant impact on the
Company's business and on the market price of the Company's
securities.
Dividends Not Likely
The Company has not paid any cash dividends on its Common Stock.
For the foreseeable future it is anticipated that earnings, if
any, which may be generated from the Company's operations will be
used to finance the growth of the Company and that cash dividends
will not be paid to holders of Common Stock.
SELLING SHAREHOLDERS
[The following table sets forth certain information regarding the
beneficial ownership of Common Stock of the Selling Shareholders
as of September 5, 1997 and as adjusted to give effect to the sale
of the Shares offered hereby. The Shares are being registered to
permit public secondary trading of the Shares, and the Selling
Shareholders may offer the Shares for resale from time to time.
See "Plan of Distribution."]
Name and Address of Number of Number of Beneficial
Selling Shares Sharesd Ownership
Shareholders Beneficially Being After Offering
Owned Prior to Offered Number of
Offering Shares Percent
Cameron Capital 1,328,037(1) 1,328,037 0 *
Ltd.
10 Cavendish Road
Hamilton HM 19,
Bermuda
Fahnestock & Co. 50,000(2) 50,000 0 *
Inc.
110 Wall Street
New York, NY 10005
__________
* Less than one percent.
(1) On July 31, 1996, Cameron Capital, Ltd. ("Cameron")
purchased a mandatorily convertible note from the Company in the
principal amount of $5,000,000 with a maturity of July 31, 1999
(the "Note"). The principal amount of the Note (or portions
thereof in minimum amounts of $100,000) became convertible on
January 31, 1997, and the remaining principal amount of the Note
will be automatically converted (if not converted in full before
then) on July 31, 1999. The conversion rate is not fixed. Rather,
when converted, the principal amount being converted will convert
at a discount from the 10-day average of the closing bid prices
for the Company's Common Stock preceding the conversion date,
ranging from 15% on January 31, 1997 to 25% on July 31, 1997 and
thereafter. The Note further provides that the maximum
permissible conversion price of the Note is $8.00 per share and
prohibits Cameron from converting principal amounts of the Note
into Common Stock if such conversion would result in Cameron
owning at any one time more than 5.0% of the Company's
outstanding shares of Common Stock.
As of the date of this prospectus, Cameron has converted
$3,087,000 of the principal amount of the Note into 700,000
shares of Common Stock of Cypros. All of these shares have been
re-sold in either negotiated or ordinary brokerage transactions
pursuant to a previously filed registration statement (No. 333-
17501) and Cameron currently owns no shares of Common Stock. For
SEC purposes, the number of shares listed above as beneficially
owned by Cameron reflects ownership by Cameron of the 700,000
shares of Common Stock acquired upon conversion of $3,087,000 of
the principal amount of the Note (prior to the subsequent resale
by Cameron) and assumes conversion of the remaining $1,913,000 in
principal amount based on a 25% discount from a 10-day average
closing bid price of $4.0625 per share. However, the filing of
this registration statement is not intended to reflect any
obligation of Cameron to convert all or any portion of the Note
immediately.
(2) Shares issuable upon exercise of a warrant issued to
Fahnestock & Co. Inc. in consideration of financial consulting
advice provided to the Company from time to time relating to
potential strategic alliances, licenses, mergers and
acquisitions. The warrant has an exercise price of $6.26 per
share and expires January 31, 2001.
PLAN OF DISTRIBUTION
The Company has been advised that the Selling Shareholders may
sell Shares from time to time, as market conditions permit on the
Nasdaq National Market System, or otherwise, through ordinary
brokerage transactions, in negotiated transactions, at fixed
prices which may be changed, at market prices prevailing at the
time of sale, at prices related to such prevailing market prices
or at negotiated prices. The Selling Shareholders may effect
such transactions by selling the Shares to or through broker-
dealers, and all such broker-dealers may receive compensation in
the form of discounts, concessions or commissions from the
Selling Shareholders and/or the purchasers of the Shares for whom
such broker-dealers may act as agent or to whom they sell as
principal, or both (which compensation as to a particular broker-
dealer might be in excess of customary commissions). The
aforementioned methods of sale may not be all-inclusive.
Any broker-dealer acquiring the Shares in the over-the-counter
market from the holder may sell the Shares either directly, in
its normal market-making activities, through or to other brokers
on a principal or agency basis or to its customers. Any such
sales may be at prices then prevailing in the over-ther-counter
market, at prices related to such prevailing market prices or at
negotiated prices to its customers or a combination of such
methods. The Selling Shareholders and any broker-dealers that act
in connection with the sale of Shares hereunder may be deemed to
be "underwriters" within the meaning of Section 2(11) of the
Securities Act; any commissions received by them and profits on
any resale of the Shares as principal might be deemed to be
underwriting discounts and commissions under the Securities Act.
Any such commissions, as well as other expenses of the Selling
Shareholders and applicable transfer taxes, are payable by such
parties, as the case may be.
The Company has agreed to indemnify the Selling Shareholders
against certain liabilities, including certain liabilities under
the Securities Act of 1933, as amended.
LEGAL MATTERS
The validity of the shares of Common Stock offered hereby have
been passed upon for the Company by Cooley Godward LLP, 4365
Executive Drive, San Diego, California 92121. As of the date of
this Prospectus, a partner of Cooley Godward LLP holds 45,625
shares of Common Stock and options to purchase 37,500 shares of
Common Stock.
EXPERTS
The financial statements of Cypros Pharmaceutical Corporation
included in Cypros Pharmaceutical Corporation's Annual Report
(Form 10-K and Forms 10-K/A) for the year ended July 31, 1996,
have been audited by Ernst & Young LLP, independent auditors,
as set forth in their reports thereon included therein and
incorporated herein by reference. Such financial statements are
incorporated herein by reference in reliance upon such reports
given upon the authority of such firm as experts in accounting
and auditing.
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934, and in accordance therewith
files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such
reports, proxy statements and other information filed by the
Company may be inspected and copied at the public reference
facilities maintained by the Commission at Room 1024, 450 Fifth
Street, N.W., Judiciary Plaza, Washington, D.C. 20549, and at
the Commission's following Regional Offices: Chicago Regional
Office, Northwestern Atrium Center, 500 West Madison Street,
Suite 1400, Chicago, Illinois 60661; and New York Regional
Office, 7 World Trade Center, New York, New York 10048. Copies
of such material can also be obtained at prescribed rates from
the Public Reference Section of the Commission at 450 Fifth
Street, N.W., Judiciary Plaza, Washington, D.C. 20549. The
Commission also maintains a site on the World Wide Web where
copies of such materials may be obtained. The address for such
site is http://www.sec.gov.
The Company has filed with the Commission a Registration
Statement on Form S-3 under the Securities Act, with respect to
the Common Stock offered hereby. This Prospectus does not
contain all of the information set forth in the Registration
Statement, certain parts of which are omitted in accordance with
the rules and regulations of the Commission. For further
information with respect to the Company and the Common Stock
offered hereby, reference is made to the Registration Statement
and the exhibits and schedules thereto, which may be inspected
without charge at, and copies thereof may be obtained at
prescribed rates from, the Public Reference Section of the
Commission at 450 Fifth Street, N.W., Judiciary Plaza,
Washington, D.C. 20549.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
[The Company's Annual Reports on Form 10-K and Forms 10-K/A for
the fiscal year ended July 31, 1996, the Company's Form 8-K
dated September 20,1996, the Company's Form 8-K dated November 4, 1996,
the Company's Form 8-K/A dated January 16, 1997, the
Company's Form 10-Q and Form 10-Q/A for the quarter ended October 31, 1996,
the Company's Form 10-Q and Form 10-Q/A for the quarter ended
January 31, 1997, the Company's Form 10-Q and Form 10-Q/A for
the quarter ended April 30, 1997, the Company's proxy statement
for the 1997 Annual Meeting of Shareholders filed pursuant to
Rule 14a-6 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and the Company's Registration Statement
on Form 8-A dated October 23, 1992 filed with the Securities
and Exchange Commission (the "Commission") are hereby incorporated
by reference in this Prospectus except as superseded or modified herein.
Additionally, the description of the Common Stock which is
contained in the Registration Statement on Form S-1 (No. 33-
51682), effective November 3, 1992, as filed with the Commission
under the Act, including any amendment or reports filed for the
purpose of updating such description, is hereby incorporated by
reference into this Prospectus and shall be deemed to be a part
hereof. All documents filed with the Commission pursuant to
Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the
date of this Prospectus and prior to the termination of the
offering and all amendments to the documents incorporated by
reference in this Prospectus shall be deemed to be incorporated
by reference into this Prospectus and to be a part hereof from
the date of filing of such documents. Any statement contained in
any document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for
purposes of this Prospectus to the extent that a statement
contained herein or in any other subsequently filed document
which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement. Any such statement so
modified or superseded shall not be deemed, except as modified or
superseded, to constitute a part of this Prospectus. The Company
will provide without charge to each person, including any
beneficial owner, to whom this Prospectus is delivered, upon
written or oral request of such person, a copy of any and all of
the documents that have been or may be incorporated by reference
herein (other than exhibits to such documents which are not
specifically incorporated by reference into such documents).
Such requests should be directed to the Vice President and Chief
Financial Officer of the Company at the Company's principal
executive offices at 2714 Loker Avenue West, Carlsbad, California
92008.]
No person is authorized in connection with any offering made
hereby to give any information or to make any representation not
contained or incorporated by reference in this Prospectus, and
any information or representation not contained or incorporated
herein must not be relied upon as having been authorized by the
Company or the Selling Shareholders. This Prospectus does not
constitute an offer to sell, or a solicitation of an offer to
buy, by any person in any jurisdiction in which it is unlawful
for such person to make such offer or solicitation. Neither the
delivery of this Prospectus at any time nor any sale made
hereunder shall, under any circumstances, imply that the
information herein is correct as of any date subsequent to the
date hereof.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth all expenses payable by the
Registrant in connection with the sale of the Common Stock being
registered. All the amounts shown are estimates except for the
SEC registration fee and the Nasdaq NMS listing application fee.
SEC Registration fee $ 1,727.91
NASDAQ NMS listing application fee 27,560.74
Legal fees and expenses 12,000.00
Accounting fees and expenses 24,000.00
Total $65,228.65
Item 15. Indemnification of Officers and Directors.
Under Section 317 of the California Corporations Code, the
Registrant is authorized to indemnify its directors, officers,
employees and other agents against liabilities they may incur in
such capacities, including liabilities under the Securities Act
of 1933, as amended. The Registrant's Bylaws provide that the
Registrant will indemnify its directors and executive officers
and may indemnify its other officers, employees and other agents
to the full extent permitted by law. The Bylaws further provide
that rights, conferred under such Bylaws shall not be deemed to
be exclusive of any other rights such persons may have or acquire
under any statute, any provisions of the Registrant's Restated
Articles of Incorporation or Bylaws, or any agreement, vote of
the shareholders or disinterested directors or otherwise.
In addition, the Registrant's Restated Articles of Incorporation
provide that to the fullest extent permitted by California law,
the Company's directors will not be personally liable for
monetary damages for breach of the directors' fiduciary duty of
care to the Company and its shareholders. This provision in the
Restated Articles of Incorporation does not eliminate the duty of
care, and in appropriate circumstances equitable remedies such as
an injunction or other forms of non-monetary relief would remain
available under California law. Each director will continue to
be subject to liability for breach of the director's duty of
loyalty to the Registrant, for acts or omissions not in good
faith or involving intentional misconduct for knowing violations
of law, for actions leading to improper personal benefit, for
acts or omissions that constitute an unexcused pattern of
inattention that amounts to an abdication of the director's duty
to the Registrant or its shareholders and for payment of
dividends, approvals of stock repurchases or redemptions or loans
or guarantees that are unlawful under California law. These
provisions do not affect a director's responsibilities under any
other laws, such as the federal securities laws or the state or
federal environmental laws.
There is no pending material litigation or proceeding involving a
director, officer, employee or other agent of the Registrant as
to which indemnification is being sought, nor is the Registrant
aware of any pending or threatened material litigation that may
result in claims for indemnification by any director, officer,
employee or other agent.
Item 16. Exhibits.
Exhibit
Number Description of Document
[5.1*] Opinion of Cooley Godward LLP.
23.1 Consent of Ernst & Young LLP, Independent Auditors.
[23.2*] Consent of Cooley Godward LLP. Reference is made to
Exhibit 5.1.
24.1* Power of Attorney. Reference is made to page 18
of the Registration Statement.]
___________________
* Previously filed.
Item 17. Undertakings.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers,
and controlling persons of the Registrant pursuant to the
provisions described in Item 15 or otherwise, the Registrant has
been advised that in the opinion of the Securities and Exchange
Commission, such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or
paid by a director, officer, or controlling person of the
Registrant in the successful defense of any action, suit, or
proceeding) is asserted by such director, officer, or controlling
person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in
the Act and will be governed by the final adjudication of such
issue.
The undersigned Registrant hereby undertakes: (1) to file, during
any period in which offers or sales are being made, a post-
effective amendment to this registration statement:
(i) to include any prospectus required by section 10(a)(3) of
the Securities Act of 1933;
(ii) to reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the
information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume
of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed
with the Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20%
change in the maximum aggregate offering price set forth in the
"Calculation of Registration Fee" table in the effective
registration statement;
(iii) to include any material information with respect to the
plan of distribution not prreviously disclosed in the
registration statement or any material change to such information
in the registration statement;
provided however, that clauses (i) and (ii) do not apply if the
information required to be included in a post-effective amendment
by these clauses is contained in periodic reports filed by the
Registrant pursuant to section 13 or section 15(d) of the
Securities Exchange Act of 1934 that are incorporated by
reference in the registration statement; (2) that, for the
purpose of determining any liability under the Securities Act of
1933, each post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof; and (3)
to remove from registration by means of a post-effective
amendment any of the securities being registered which remain
unsold at the termination of the offering.
The undersigned Registrant hereby undertakes: (1) for purpose of
determining any liability under the Securities Act of 1933, the
information omitted from the form of prospectus filed as part of
the registration statement in reliance upon Rule 430A and
contained in the form of prospectus filed by the Registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of the registration statement as
of the time it was declared effective; (2) for the purpose of
determining any liability under the Securities Act of 1933, each
post-effective amendment that contains a form of prospectus shall
be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering
thereof; and (3) for purposes of determining any liability under
the Securities Act of 1933, each filing of the Registrant's
annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each
filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Securities Exchange Act of 1934) that is
incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering
thereof.
SIGNATURES
[Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-3 and
has duly caused this Amendment No. 2 to Registration Statement to
be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of San Diego, County of San Diego, State
of California, on the 8th day of September, 1997.]
CYPROS PHARMACEUTICAL CORPORATION
By: /s/ Paul J. Marangos
- --------------------------
Paul J. Marangos
Chairman of the Board,
President and Chief Executive Officer
(Principal executive officer)
*
[Pursuant to the requirements of the Securities Act of 1933, this
Amendment No. 2 to Registration Statement has been signed below
by the following persons in the capacities and on the dates
indicated.]
Signature Title Date
/s/ Paul J. Marangos Chairman of the [September 8, 1997]
- -------------------- Board, President and
Paul J.Marangos Chief Executive
Officer
(Principal executive
officer)
/s/ David W. Nassif Vice President, [September 8, 1997]
- -------------------- Chief Financial
Officer and
David W. Nassif Secretary
(Principal financial
and accounting
officer)
* Director [September 8, 1997]
- --------------------
Digby W. Barrios
* Director [September 8, 1997]
- --------------------
Robert F. Allnutt
* Director [September 8, 1997]
- --------------------
Virgil D.Thompson
* Director [September 8, 1997]
- --------------------
Robert A. Vukovich
* /s/ David W. Nassif
By:------------------------
David W. Nassif, Attorney-in-fact
INDEX TO EXHIBITS
Sequentially
Exhibit Number Description Numbered Page
23.1 Consent of Ernst & 21
Young LLP,
Independent Auditors
Exhibit 23.1
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
[We consent to the reference to our firm under the caption
"Experts" in Amendment No. 2 to the Registration Statement (Form
S-3) and related Prospectus of Cypros Pharmaceutical Corporation
for the registration of shares of its common stock and to the
incorporation by reference therein of our report dated August 26,
1996, with respect to the financial statements of Cypros Pharmaceutical
Corporation included in its Annual Report (Form 10-K) for the
year ended July 31, 1996, as amended, as filed on Forms 10-K/A
filed with the Securities and Exchange
Commission.]
ERNST & YOUNG LLP
(Signature)
San Diego, California
[September 4, 1997]
